The biopharma industry is navigating a turbulent policy landscape as Novartis CEO warns Trump's drug pricing reforms will reshape market realities over the next 18 months. Meanwhile, innovation continues apace: Boehringer Ingelheim posted compelling Phase 3 obesity data, Intellia initiated its first CRISPR therapy filing, and Eli Lilly struck a deal to leapfrog CRISPR with AI-designed gene editors. BioMarin closed its $4.8 billion acquisition of Amicus Therapeutics to deepen its rare disease portfolio, and Purdue Pharma edges closer to resolving its opioid bankruptcy.
Top Stories
Novartis CEO Warns Trump Drug Pricing Policy Poses 'Very Difficult Situation' for Industry
Novartis CEO Vas Narasimhan cautioned that the reality of President Trump's most-favored-nation drug pricing policy will become apparent over the next 18 months, describing it as a "very difficult situation" for drugmakers and patients, according to CNBC. The comments, made during an earnings discussion, signal rising industry anxiety about potential margin compression and access implications as implementation details crystallize. This represents the most direct public warning yet from a major pharma CEO about the policy's downstream consequences.
Boehringer Ingelheim's Dual-Acting Obesity Shot Delivers 16.6% Weight Loss in Phase 3
Boehringer Ingelheim's survodutide achieved "Wegovy-like" efficacy with 16.6% mean weight loss in Phase 3 testing, BioPharma Dive reported, with STAT noting that additional data will be needed to assess competitive positioning. The dual GLP-1/glucagon agonist showed promising signals for muscle mass preservation, a key differentiator in the crowded obesity market. This positions Boehringer as a credible third entrant behind Novo Nordisk and Eli Lilly, though investors will scrutinize upcoming cardiovascular and comparative efficacy data.
Intellia Begins Rolling BLA Submission for First In Vivo CRISPR Therapy in Hereditary Angioedema
Intellia Therapeutics initiated a rolling biologics license application to the FDA for lonvoguran ziclumeran (lonvo-z), its investigational one-time CRISPR therapy for hereditary angioedema, according to Big Molecule Watch. The therapy, previously NTLA-2002, is designed as an outpatient-administered treatment using in vivo gene editing to silence the KLKB1 gene. This filing marks a watershed moment for the CRISPR field, representing the first regulatory submission for a directly-administered gene editing therapeutic rather than an ex vivo cell therapy.
Eli Lilly Partners with Profluent to Deploy AI-Designed Gene Editors Beyond CRISPR
Eli Lilly signed a deal worth up to $2.25 billion with AI startup Profluent to develop next-generation gene editing tools that can insert entire genes rather than merely cutting DNA, Fierce Biotech and STAT reported. The collaboration aims to leverage computationally designed enzymes to overcome limitations of conventional CRISPR systems, potentially enabling treatment of previously undruggable genetic diseases. The move signals pharma's growing conviction that AI-native biology platforms could reshape genetic medicine within the decade.
BioMarin Acquires Amicus Therapeutics for $4.8 Billion, Expanding Rare Disease Portfolio
BioMarin Pharmaceutical completed its $4.8 billion all-cash acquisition of Amicus Therapeutics at $14.50 per share on April 28, adding Fabry disease treatment Galafold (migalastat) and Pompe disease combination therapy Pombiliti + Opfolda to its rare disease franchise, Pharmaceutical Technology reported. Amicus generated $6.2 billion in revenue in 2025 with products approved in more than 40 countries, and also brings Phase 3 candidate DMX-200 for focal segmental glomerulosclerosis. The deal strengthens BioMarin's position as a leading rare disease specialist, leveraging its global commercial infrastructure and in-house manufacturing capabilities to scale Amicus's portfolio.
Incyte's Povorcitinib Hits in Twin Phase 3 Vitiligo Trials, Plans Regulatory Filing
Incyte reported positive results from two Phase 3 studies of povorcitinib, its oral JAK1 inhibitor, in nonsegmental vitiligo and plans to file for regulatory approval in the second half of 2026, according to Endpoints News. The twin successes position Incyte to expand its JAK franchise beyond established indications into dermatology, where oral administration offers convenience advantages over topical competitors. This signals growing confidence that selective JAK1 inhibition can achieve meaningful repigmentation without broader JAK inhibitor safety concerns.
Purdue Pharma Nears Finalization of Bankruptcy Plan to Resolve Opioid Litigation
OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy deal that could conclude years of opioid liability litigation, pharmaphorum reported. The resolution would mark a major milestone in the industry's protracted legal battles over prescription opioid marketing and distribution practices. The structure and precedential value of any final settlement will shape liability exposure calculations for other defendants still facing claims.
Devoted Health Revenue and Membership Decline in Turbulent Medicare Advantage Market
Devoted Health posted its first-ever revenue and membership decline since launching seven years ago, reflecting broader headwinds in the Medicare Advantage sector, Endpoints News reported. The high-profile startup, founded by former Athenahealth executives, is navigating intensified competition and regulatory rate pressure affecting the entire MA market. This underscores growing questions about the sustainability of venture-backed insurance models as reimbursement environments tighten.
What to Watch
- MFN Implementation Details — Watch for specifics on Trump's drug pricing policy rollout over the next six quarters; Novartis CEO's 18-month timeline suggests major announcements or enforcement actions are imminent.
- Boehringer Obesity Program Expansion — Additional cardiovascular outcomes and muscle composition data will determine whether survodutide can command Wegovy-level pricing and market share in the $100B+ obesity opportunity.
- CRISPR Regulatory Pathway — Intellia's rolling BLA will establish precedents for in vivo gene editing approvals; FDA's review rigor and timeline will signal regulatory appetite for directly-administered genetic medicines.
- AI-Biology Deals Proliferate — Lilly's Profluent partnership may accelerate similar AI-platform deals as pharma seeks computational shortcuts to novel modalities beyond traditional antibody and small molecule discovery.
- Rare Disease Consolidation — BioMarin's Amicus acquisition creates a broader rare disease platform; watch for integration execution and whether Galafold and Pombiliti + Opfolda accelerate under BioMarin's global commercial footprint.
Market Snapshot
- Obesity Market Dynamics: Boehringer's competitive Phase 3 data intensifies the three-way race with Novo and Lilly, potentially compressing long-term pricing power as payers gain negotiating leverage with multiple effective GLP-1 options.
- Medicare Advantage Pressure: Devoted Health's first-ever revenue decline signals sector-wide reimbursement headwinds that could reshape payer strategies and curtail aggressive expansion plans across venture-backed insurance entrants.
- Gene Editing Inflection: With Intellia's BLA and Lilly's AI-editor deal, the genetic medicine sector is shifting from ex vivo proof-of-concept to scalable in vivo therapeutics, expanding addressable patient populations by orders of magnitude.